Aug 27 (Reuters) - CanSino Biologics Inc :
* HY REVENUE RMB2.06 BILLION
* HY OPERATING PROFIT RMB 802.3 MILLION
* UNABLE TO ACCURATELY PREDICT EXTENT OF IMPACT OF PANDEMIC ON BUSINESS OPERATIONS
* EXPANDING SALES, MARKETING TEAM TO FURTHER SALES OF COMMERCIALIZED PRODUCTS, PREPARE FOR NEAR COMMERCIAL-STAGE PRODUCTS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
精彩评论